Current Report Filing (8-k)
December 08 2016 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 6, 2016
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36500
|
|
94-3103561
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address
of principal executive offices)
(510) 293-8800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 6, 2016, the CymaBay Therapeutics, Inc.
Board of Directors (the Board) appointed Robert Booth, Ph.D. and Caroline Loewy as members of the Board. Further, Dr. Booth was appointed as a member of the Compensation Committee and Ms. Loewy was appointed as a member of the Audit
Committee. Dr. Booth and Ms. Loewy will each serve until CymaBays 2017 Annual Meeting of Stockholders or until his or her earlier death, resignation or removal and will be entitled to receive compensation as a non-employee director of CymaBay
under CymaBays currently effective non-employee director compensation policy, which was filed as Exhibit 10.20 to CymaBays Annual Report on Form 10-K on March 23, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
CymaBay Therapeutics, Inc.
|
|
|
By:
|
|
/s/ Sujal Shah
|
|
|
|
Name:
|
|
Sujal Shah
|
Title:
|
|
Chief Financial Officer
|
Dated: December 8, 2016
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Sep 2023 to Sep 2024